Compare Recursion Pharmaceuticals Inc (RXRX) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $4 (market cap $2.14B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.88 (market cap $3.39B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is the larger of the two by market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| RXRX | SPUS | |
|---|---|---|
Market Cap | $2.14B | $3.39B |
Volume | 30,789,535 | 349,184 |
Sector | Health | Broad Market / Factor |
52-Week High | $6.79 | $61.15 |
52-Week Low | $2.84 | $46.65 |
Typical Hold Time | 22 Days | 64 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
